Cevoglitazar (LBM-642; LBM642) is a novel and potent PPARɑ agonist and PPARγ agonist with the potential to be used for the treatment of type 2 diabetes. It potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Cevoglitazar was as effective as pioglitazone at improving glucose tolerance.

纯度：≥98%

CAS：839673-52-8